Premium
Allogeneic blood progenitor cell collection in normal donors after mobilization with filgrastim: the M.D. Anderson Cancer Center experience
Author(s) -
Anderlini P.,
Donato M.,
Chan K.W.,
Huh Y.O.,
Gee A.P.,
Lauppe M.J.,
Champlin R.E.,
Körbling M.
Publication year - 1999
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1046/j.1537-2995.1999.39060555.x
Subject(s) - filgrastim , leukapheresis , medicine , apheresis , adverse effect , surgery , granulocyte colony stimulating factor , transplantation , chemotherapy , cd34 , stem cell , platelet , biology , genetics
BACKGROUND: Information on the safety and efficacy of allogeneic peripheral blood progenitor cell (PBPC) collection in filgrastim‐mobilized normal donors is still limited. STUDY DESIGN AND METHODS: The PBPC donor database from a 42‐month period (12/94‐5/98) was reviewed for apheresis and clinical data related to PBPC donation. Normal PBPC donors received filgrastim (6 μg/kg subcutaneously every 12 hours) for 3 to 4 days and subsequently underwent daily leukapheresis. The target collection was ≥4 × 10 6 CD34+ cells per kg of recipient's body weight. RESULTS: A total of 350 donors were found to be evaluable. Their median age was 41 years (range, 4‐79). Their median preapheresis white cell count was 42.8 × 10 9 per L (range, 18.3‐91.6). Of these donors, 17 (5%) had inadequate peripheral venous access. Leukapheresis could not be completed because of apheresis‐related adverse events in 2 donors (0.5%). Of the 324 donors evaluable for apheresis yield data, 221 (68%) reached the collection target with one leukapheresis. The median CD34+ cell dose collected (first leukapheresis) was 462 × 10 6 (range, 29‐1463). The main adverse events related to filgrastim administration in donors evaluable for toxicity (n = 341) were bone pain (84%), headache (54%), fatigue (31%), and nausea (13%). These events were rated as moderate to severe (grade 2‐3) by 171 (50%) of the donors. In 2 donors (0.5%), they prompted the discontinuation of filgrastim administration. CONCLUSION: PBPC apheresis for allogeneic transplantation is safe and well tolerated. It allows the collection of an “acceptable” PBPC dose in most normal donors with one leukapheresis, with minimal need for invasive procedures.